RxDoctor Payments Data

Nicholas Dubois, MD

Cardiovascular Disease · New York, NYNPI 1932113636

Payments from drug & device makers

$728in general payments, 2019–2025

Across 17 payments — averaging $42.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$330
  • E.r. Squibb & Sons, L.L.C.$280
  • Philips North America LLC$89
  • Abbott$29

What the payments were for

  • Food & beverage$728100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)2$330
E.r. Squibb & Sons, L.L.C.12$280
Philips North America LLC2$89
Abbott1$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$728 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$477,597
Medicare patients
1,230
Services billed
4,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban413$535,079
XareltoRivaroxaban117$147,384
JardianceEmpagliflozin107$128,428
Repatha SureclickEvolocumab103$110,689
Praluent PenAlirocumab51$52,112
MultaqDronedarone Hcl27$38,170
FarxigaDapagliflozin Propanediol22$31,637
EntrestoSacubitril/Valsartan16$27,823
Metoprolol Succinate697$11,103
Rosuvastatin Calcium612$10,184
Atorvastatin Calcium640$8,385
Ezetimibe210$7,386
Losartan Potassium423$5,321
Amlodipine Besylate524$4,193
CozaarLosartan Potassium14$3,613

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →